MODICON 28 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Modicon 28, and when can generic versions of Modicon 28 launch?
Modicon 28 is a drug marketed by Janssen Pharms and is included in one NDA.
The generic ingredient in MODICON 28 is ethinyl estradiol; norethindrone. There are twenty-six drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norethindrone profile page.
Summary for MODICON 28
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 7 |
Patent Applications: | 166 |
Formulation / Manufacturing: | see details |
DailyMed Link: | MODICON 28 at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for MODICON 28
US Patents and Regulatory Information for MODICON 28
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Janssen Pharms | MODICON 28 | ethinyl estradiol; norethindrone | TABLET;ORAL-28 | 017735-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |